Molecular Partners (MOLN) Stock Price, News & Analysis

Company Overview

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology. Its lead DARPin candidate, ensovibep, was advanced through clinical trials for the treatment of COVID-19, highlighting the platform’s flexibility in addressing emerging viral threats. In ophthalmology, Molecular Partners is investigating abicipar, a DARPin eye injection designed to extend treatment intervals for patients with neovascular age-related macular degeneration. Additional programs focus on oncology targets, with several preclinical candidates designed to engage multiple cancer‐related pathways simultaneously.

Founded in 2004 as a spin‐off from research at the University of Zurich, Molecular Partners has established collaborations with major pharmaceutical companies to accelerate development and commercialization of its DARPin products. Partnerships with organizations such as Novartis and Roche have enabled access to global development expertise and expanded the reach of its clinical programs. The company maintains operations in Europe and the United States, positioning it to engage with regulators and strategic partners across key markets.

The leadership team is led by Chief Executive Officer Patrick Amstutz, who brings extensive experience in oncology and biologics development. Under his guidance, Molecular Partners has grown from an early‐stage research entity into a publicly traded company listed on the Nasdaq Global Select Market under the symbol MOLN. The company continues to advance its DARPin platform through a combination of internal innovation and collaborative alliances, with the goal of bringing differentiated therapies to patients worldwide.

Key Stats

• Today's Range: $4.20 to $4.24
• 50-Day Range: $3.75 to $5.10
• 52-Week Range: $3.41 to $5.36
• Volume: 1,946 shs
• Average Volume: 4,059 shs
• Market Capitalization: $168.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.38
• Consensus Rating: Hold

Molecular Partners Stock Analysis - MarketRank™

Molecular Partners scored higher than 67% of companies evaluated by MarketBeat, and ranked 237th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Molecular Partners has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Molecular Partners has a consensus price target of $8.38, representing about 91.2% upside from its current price of $4.38.

Amount of Analyst Coverage

Molecular Partners has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Molecular Partners are expected to grow in the coming year, from ($1.40) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Molecular Partners is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Molecular Partners is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Molecular Partners has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of Molecular Partners has been sold short.

Short Interest Ratio / Days to Cover

Molecular Partners has a short interest ratio ("days to cover") of 3.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Molecular Partners has recently decreased by 20.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Molecular Partners does not currently pay a dividend.

Dividend Growth

Molecular Partners does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.62

News Sentiment

Molecular Partners has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Molecular Partners this week, compared to 1 article on an average week.

Search Interest

3 people have searched for MOLN on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Molecular Partners insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.93% of the stock of Molecular Partners is held by insiders.

Percentage Held by Institutions

26.55% of the stock of Molecular Partners is held by institutions.

MOLN Stock Analysis - Frequently Asked Questions

How have MOLN shares performed this year?

Molecular Partners' stock was trading at $4.4450 on January 1st, 2026. Since then, MOLN stock has decreased by 1.5% and is now trading at $4.38.

How were Molecular Partners' earnings last quarter?

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) announced its earnings results on Thursday, March, 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.03.

When did Molecular Partners IPO?

Molecular Partners (MOLN) raised $64 million in an initial public offering (IPO) on the week of June 14th 2021. The company issued 3,000,000 shares at a price of $21.25 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager.

Who are Molecular Partners' major shareholders?

Top institutional investors of Molecular Partners include SmartHarvest Portfolios LLC (0.04%).

How do I buy shares of Molecular Partners?

Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Molecular Partners own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Partners investors own include PayPal (PYPL), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Robinhood Markets (HOOD), Taiwan Semiconductor Manufacturing (TSM) and Adobe (ADBE).

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MOLN
• CIK: 1745114
• Web: www.molecularpartners.com
• Phone: 41-44-755-7700
• Fax: N/A
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Molecular Partners: $8.38
• High Price Target: $13.00
• Low Price Target: $3.75
• Potential Upside/Downside: +100.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.62%
• Return on Assets: -51.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.78
• Quick Ratio: 8.79

Sales & Book Value

• Annual Sales: $5.65 million
• Price / Sales: 29.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.40 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 40,380,000
• Free Float: 37,981,000
• Market Cap: $168.42 million
• Optionable: Not Optionable
• Beta: 1.08